Premenstrual syndrome: Current aspects of classification, diagnosis, and treatment


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

A wide variety of symptoms of premenstrual disorders is due to different causes; however, the trigger mechanism is similar; that is ovulation. Oral contraceptives containing drospirenone as a gestagenic component are the most effective approach to suppressing ovulation.

Full Text

Restricted Access

About the authors

Ara Leonidovich Unanyan

I.M. Sechenov First Moscow State Medical University

Email: 9603526@mail.ru
Doctor of Medicine, professor of obstetrics and gynecology №1

Sergey Ernestovich Arakelov

City Clinical Hospital Fifty-Three; Peoples' Friendship University of Russia

Email: 53mosgkb@gmail.com
MD, Chief Physician Hospital № 53 Moscow, assistant professor of obstetrics and gynecology PFUR Moscow

Lusine Surenovna Polonskaya

City Clinical Hospital Fifty-Three

Email: ml.795l447@gmail.com
MD, head of gynecology department Physician Moscow

Taymuraz Dudaevich Guriev

I.M. Sechenov First Moscow State Medical University

Email: 9603526@mail.ru
Doctor of Medicine, professor of obstetrics and gynecology

Vera Dmitriyevna Morozova

I.M. Sechenov First Moscow State Medical University

Email: 9603526@mail.ru
MD, Associate Professor of Psychiatry and Addiction

References

  1. Прилепская В.Н., Межевитинова Е.А., Назарова Н.М., Новикова Е.П., Сасунова Р.А. Лечебные возможности современной гормональной контрацепции. Акцент на дроспиренонсодержащее соединение с новым режимом дозирования. Гинекология. 2012; 1: 42-5. [Prilepskaya V.N. Mezhevitinova E.A., Nazarov N.M., Novikova E.P., Sasunova R.A. Therapeutic possibilities of modern hormonal contraception. Emphasis on dro-spirenonsoderzhaschee connection with a new dosing schedule. Gynecology, 2012; 1: 42-45].
  2. Кузнецова И.В., Коновалов В.А. Пролонгированный прием комбинированного орального контрацептива, содержащего дроспиренон, в лечении предменструального синдрома. Проблемы репродукции. 2008; 4: 28-31. [Kuznetsova I.V., Konovalov V.A. Prolonged combined oral contraceptive containing drospirenone in the treatment of premenstrual syndrome. Problems of reproduction. 2008; 4: 28-31].
  3. ACOG Committee on Practice Bulletins--Gynecology. ACOG practice bulletin: no 15: Premenstrual syndrome. Obstet. Gynecol. 2000; 95(4, Suppl.): 1-9.
  4. Brown J., O’Brien P.M., Marjoribanks J., Wyatt K. Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database Syst. Rev. 2009; (2): CD001396.
  5. Coffee A.L., Kuehl T.J., Willis S., Sulak P.J. Oral contraceptives and premenstrual symptoms: comparison of a 21/7 and extended regimen. Am. J. Obstet. Gynecol. 2006; 156: 1311-9.
  6. Fathizadeh N., Ebrahimi E., Valiani M., Tavakoli N., Yar M.H. Evaluating the effect of magnesium and magnesium plus vitamin B6 supplement on the severity of premenstrual syndrome. Iran J. Nurs. Midwifery Res. 2010; 15(Suppl. 1): 401-5.
  7. Frank R.T. The hormonal causes of premenstrual tension. Arch. Neurol. Psychiatry. 1931; 26: 1053-7.
  8. Grady-Weliky T.A. Clinical practice. Premenstrual dysphoric disorder. N. Engl. J. Med. 2003; 348: 433-8.
  9. Hahn P.M., Van Vugt D.A., Reid R.L. A randomized, placebo-controlled, crossover trial of danazol for the treatment of premenstrual syndrome. Psychoneuroendocrinology. 1995; 20: 193-209.
  10. Joffe H.,Petrillo L.F., Viguera A.C., Gottshcall H., Soares C.N., Hall J.E., Cohen L.S. Treatment of premenstrual worsening of depression with adjunctive oral contraceptive pills: a preliminary report. J. Clin. Psychiatry. 2007; 68(12): 1954-62.
  11. Leminen H., Paavonen J. PMS and PMDD. Duodecim. 2013; 129(17): 1756-63.
  12. Lopez L.M., Kaptein A.A., Helmerhorst F.M. Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst. Rev. 2012; (2): CD006586. doi: 10.1002/14651858.CD006586.pub4.
  13. O’Brien P.M., Backstrom T., Brown C., Dennerstein L., Endicott J., Epperson C.N. et al. Towards a consensus on diagnostic criteria, measurement and trial design of the premenstrual disorders: the ISPMD Montreal consensus. Arch. Womens Ment. Health. 2011; 14(1): 13-21.
  14. Oelkers W., Helmerhorst F.M., Wuttke W. Effect of an oral contraceptives containing drospirenone on the rennin-angiotensin-aldosterone system in healthy female volunteers. Gynecol. Endocrinol. 2006; 14: 204-13.
  15. Oelkers W. Drospirenone, a progestogen with antimineralocorticoid properties: a short review. Mol. Cell. Endocrinol. 2004; 17 (1-2): 255-61.
  16. Rapkin A.J., Chang L.C., Reading A.E. Comparison of retrospective and prospective assessment of premenstrual symptoms. Psychol. Rep. 1988; 62: 55-60.
  17. Rapkin A.J., Winer S.A. The pharmacologic management of premenstrual dysphoric disorder. Expert Opin. Pharmacother. 2008; 9: 1-17.
  18. Sitruk-Ware R. Pharmacological profile of progestins. Maturitas. 2008; 61 (1-2): 151-7.
  19. Steiner M., Pearlstein T., Cohen L.S., Endicott J., Kornstein S.G., Roberts C. et al. Expert guidelines for the treatment of severe PMS, PMDD, and co morbidities: the role of SSRIs. J. Womens Health (Larchmt). 2006; 15: 57-69.
  20. Tuccori M., Testi A., Antonioli L., Fornai M., Montagnani S., Ghisu N. et al. Safety concerns associated with the use of serotonin reuptake inhibitors and other serotonergic/noradrenergic antidepressants: a review. Clin. Ther. 2009; 31: 1426-53.
  21. Verma R.K., Chellappan D.K., Pandey A.K. Review on treatment of premenstrual syndrome: from conventional to alternative approach. J. Basic Clin. Physiol. Pharmacol. 2014; Mar 12.
  22. Wang M., Hammarback S., Lindhe B.A., Backstrom T. Treatment of premenstrual syndrome by spironolactone: a double-blind, placebo-controlled study. Acta Obstet. Gynecol. Scand. 1995; 74: 803-8.
  23. World Health Organization (WHO). International classification of diseases. 10th ed. Geneva: WHO; 1996
  24. Wyatt K., Dimmock P., Jones P., Obhrai M., O’Brien S. Efficacy of progesterone and progestogens in management of premenstrual syndrome: systematic review. Br. Med. J. 2001; 323(7316): 776-80.
  25. Wyatt K.M., Dimmock P.W., Ismail K.M., Jones P.W., O’Brien P.M. The effectiveness of GnRHa with and without “add-back” therapy in treating premenstrual syndrome: a meta-analysis. Br. J. Obstet. Gynaecol. 2004; 111(6): 585-93.
  26. Wyatt K.M., Dimmock P.W., Jones P.W., O’Brien P.M. Efficacy of vitamin B6 in the treatment of premenstrual syndrome: a systematic review. Br. Med. J. 1999; 318(7195): 1375-81.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies